Conference Coverage

Universal BRCA testing worthwhile for relatives of high-grade serous ovarian cancer patients


 

REPORTING FROM ACOG 2018


“Any opportunity to prevent ovarian cancer is worthwhile,” Dr. Kwon commented. “If an ovarian cancer patient cannot be tested because she declines testing or, more commonly, because she is deceased, her first-degree relative should have BRCA mutation testing, regardless of other personal or family history or ethnicity.”

She and her coinvestigators reported no relevant financial disclosures.

Pages

Recommended Reading

New multi-analyte blood test shows promise in screening for several common solid tumors
MDedge Internal Medicine
USPSTF: Routine screens for ovarian cancer not recommended
MDedge Internal Medicine
Telling her she has cancer: A patient-centered approach to breaking bad news
MDedge Internal Medicine
FDA authorizes first direct-to-consumer BRCA1/2 test
MDedge Internal Medicine
Chlamydia infections associated with more than a doubling of ovarian cancer risk
MDedge Internal Medicine
Same-day discharge for hysterectomy
MDedge Internal Medicine
Study: No increased risk of serious AEs with combined urogyn/gyn onc surgery
MDedge Internal Medicine
VIDEO: Indocyanine green finds more sentinel lymph nodes
MDedge Internal Medicine
What is HIPEC?
MDedge Internal Medicine
Leg lymphedema after gynecologic lymphadenectomy exceeds expectations
MDedge Internal Medicine